收费全文 | 5097篇 |
免费 | 269篇 |
国内免费 | 30篇 |
耳鼻咽喉 | 36篇 |
儿科学 | 75篇 |
妇产科学 | 63篇 |
基础医学 | 583篇 |
口腔科学 | 149篇 |
临床医学 | 282篇 |
内科学 | 1364篇 |
皮肤病学 | 92篇 |
神经病学 | 381篇 |
特种医学 | 291篇 |
外科学 | 852篇 |
综合类 | 20篇 |
预防医学 | 237篇 |
眼科学 | 129篇 |
药学 | 296篇 |
中国医学 | 22篇 |
肿瘤学 | 524篇 |
2023年 | 23篇 |
2022年 | 20篇 |
2021年 | 106篇 |
2020年 | 84篇 |
2019年 | 110篇 |
2018年 | 125篇 |
2017年 | 87篇 |
2016年 | 102篇 |
2015年 | 97篇 |
2014年 | 157篇 |
2013年 | 196篇 |
2012年 | 308篇 |
2011年 | 345篇 |
2010年 | 221篇 |
2009年 | 178篇 |
2008年 | 246篇 |
2007年 | 277篇 |
2006年 | 294篇 |
2005年 | 298篇 |
2004年 | 265篇 |
2003年 | 282篇 |
2002年 | 240篇 |
2001年 | 133篇 |
2000年 | 122篇 |
1999年 | 115篇 |
1998年 | 42篇 |
1997年 | 48篇 |
1996年 | 36篇 |
1995年 | 38篇 |
1994年 | 33篇 |
1993年 | 29篇 |
1992年 | 63篇 |
1991年 | 55篇 |
1990年 | 52篇 |
1989年 | 64篇 |
1988年 | 62篇 |
1987年 | 47篇 |
1986年 | 45篇 |
1985年 | 52篇 |
1984年 | 41篇 |
1983年 | 31篇 |
1982年 | 18篇 |
1981年 | 13篇 |
1980年 | 13篇 |
1979年 | 28篇 |
1978年 | 18篇 |
1977年 | 24篇 |
1975年 | 14篇 |
1974年 | 19篇 |
1969年 | 12篇 |
Background
The negative impact of postoperative complications (POCs) on long-term outcomes is well documented for several cancer surgeries, but conclusive evidence has yet to be provided on the influence of POCs on long-term oncological outcomes after hepatic resection for colorectal liver metastasis (CRLM).Methods
Studies published through February 2012 evaluating the oncological impact of POCs after hepatectomy for CRLM were identified by an electronic literature search. Finally, 4 studies were identified and included in the meta-analysis. The main outcome measures were 5-year disease-free survival (DFS) and overall survival (OS). A meta-analysis was performed using the DerSimonian-Laird random-effects models to compute odds ratio (OR) along with 95 % confidence intervals (95 % CI).Results
The outcomes of 2,280 patients were studied. Meta-analysis of 5-year DFS data extracted from three studies demonstrated a significant reduction in 5-year DFS after POCs, with an OR of 1.98 (95 % CI = 1.33–2.96; P = .0008). Meta-analysis of 5-year OS data extracted from four studies demonstrated a significant reduction in 5-year OS after POCs, with an OR of 1.68 (95 % CI = 1.25–2.27; P = .0006). No differences between study heterogeneity were observed in either the DFS or the OS analyses.Conclusions
This study provides persuasive evidence that POCs following hepatic resection for CRLM have significant adverse oncological outcomes. These findings emphasize the need for meticulous surgical technique and careful perioperative management to minimize POCs. 相似文献Enteral nutrition (EN) is effective in Crohn’s disease (CD) patients and has been shown to have an inhibitory effect on loss of response to anti-tumor necrosis factor (TNF)-alpha antibody therapy; however, the current level of evidence is not sufficient. The objective of this meta-analysis was to determine whether EN in combination anti-TNF-alpha antibody therapy is useful in maintaining remission. PubMed was used to identify all relevant studies. A total of nine articles were identified including one randomized control trial, two prospective cohort studies, and six retrospective cohort studies. We performed a meta-analysis on all these articles to assess the remission maintenance effect of EN (n = 857). The remission or response maintenance effect in the EN group was 203/288 (70.5%), which was higher than 306/569 (53.8%) in the non-EN group. The odds ratio for long-term remission or response using fixed effects model and random effects model were 2.23 (95% CI 1.60–3.10) and 2.19 (95% CI 1.49–3.22), respectively. The usefulness of EN was unclear in two prospective studies that were conducted immediately after remission induction with anti-TNF-alpha antibody therapy was detected. Differences in the definition of relapse and the observation period among articles were considered to be limitations. This analysis suggests that EN is effective for maintaining remission in patients already in remission or response as a result of anti-TNF-alpha antibody maintenance therapy.
相似文献It is crucial to identify risk factors for life prognosis after hepatitis C virus (HCV) eradication among patients with or without a high risk of liver cancer or complications.
MethodsThis is a prospective, multicenter and observational study using the database of 1031 patients after HCV eradication by direct-acting antiviral agents (DAAs) to evaluate the development of hepatocellular carcinoma (HCC) and patients’ survival after a sustained virological response (SVR). The Cox proportional hazards regression model was used to estimate hazard ratios associated with HCC development and survival.
ResultsAFP at SVR was significantly associated with HCC recurrence in the adjusted model. Liver fibrosis, Mac-2 binding protein glycosylation isomer (M2BPGi) at SVR and smoking status before treatment were positively associated with the development of HCC and M2BPGi was positively associated with HCC recurrence, although not reaching statistical significance. Among patients without a history of HCC, M2BPGi and estimated glomerular filtration rate (eGFR) at SVR were significantly associated with death after viral eradication [M2BPGi (HR 4.07, 95% CI 1.22, 13.57), eGFR (HR 0.97, 95% CI 0.94, 0.99)]. Strikingly, of 16 patients who died, among participants without a history of HCC, only two died of liver cancer associated with HCV, whereas 11 died of non-HCV- related cancer or cardiovascular diseases.
ConclusionM2BPGi at SVR is a potential predictor for patients’ survival and a candidate biomarker for detecting individuals who are at greater risk of death due to cancer-related and unrelated to HCV, as well as cardiovascular diseases, after viral eradication.
相似文献